Life sciences briefing: Friday, Nov. 30, 2007
Featured companies: Fate Therapeutics, Medgenics, Satoris
UPDATED: Expanded items on Fate Therapeutics and Medgenics. The Satoris item is now a standalone post here.
Fate Therapeutics launches regenerative-medicine quest with $12M — In one of the splashiest launches in recent memory, Seattle’s Fate Therapeutics launched a new regenerative-medicine quest and… Continue Reading
Healthcare IT co. MedAssets sets IPO range, aims for $221M
MedAssets, an Alpharetta, Ga., provider of IT and services designed to maximize hospital revenue, said it plans to sell as many as 13.8 million shares at a price of $14 to $16 apiece, for a maximum IPO take of $221 million. The company’s latest SEC… Continue Reading
IPO roundup: Broncus Tech aims to breathe in $86M, Aegerion Pharma rides again, and more
Broncus Tech, medical device maker, files for $86M IPO — Broncus Technologies, a Mountain View, Calif., developer of minimally invasive devices for treating emphysema, filed to raise $86 million in an initial offering. The company’s SEC filing is here.
The Broncus technology is a minimally invasive,… Continue Reading
Life sciences briefing: Thursday, Nov. 15, 2007
Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma
EXPANDING ITEMS: Stay tuned.
Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart… Continue Reading
EnteroMedics and its risky obesity device, the latest victims of the IPO haircut
(UPDATED: See below.)
(NOTE: This item was originally published as part of today’s life-sciences briefing.)
EnteroMedics, a St. Paul, Minn., device maker working on a neuromodulation implant for treating obesity, slashed its expected IPO pricing by half, lowering it to a range of $8 to $9 instead of… Continue Reading
Life sciences briefing: Wednesday, Nov. 14, 2007
Featured companies: Advanced Bio-Surfaces, Ambit Biosciences, EnteroMedics, Molecular Vision, Skyline Ventures
UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here.
Skyline Ventures raises $350M life-sciences fund — Skyline Ventures, a Palo Alto, Calif., VC firm, closed a $350 million fund… Continue Reading
IPOs: Biotech ChemoCentryx and specialty-pharma Xanodyne head for the public market
ChemoCentryx files for $58M IPO to fund autoimmune, inflammation drug — Mountain View, Calif.-based ChemoCentryx, a biotech focused on new small-molecule drugs that affect a class of biochemical signals known as chemokines, filed to raise $57.5 million in an initial offering. The company’s SEC filing… Continue Reading
Life sciences briefing: Monday, Nov. 12, 2007
(UPDATED: See below.)
Featured companies: Anaptys Biosciences, Arterial Remodeling Technologies, Cambria Biosciences, CaseNet, ChemoCentryx, Ensemble Discovery, MediQuest, Piedmont Pharmaceuticals, Raven Biotechnologies, Sensys Medical, Verus Pharmaceuticals, Xanodyne Pharmaceuticals
UPDATED: Expanded items on Anaptys, Arterial Remodeling, Raven Biotech, Sensys and MediQuest. Moved ChemoCentryx and Xanodyne to a separate item.
Antibody-drug maker Raven Biotech… Continue Reading
Life sciences briefing: Wednesday, Nov. 7, 2007
Featured companies: Aryx Therapeutics, BioForm Medical, Health Market Science, Hypobaric Therapeutics, Mobile Medical International
UPDATED: Expanded items on BioForm, Aryx, Hypobaric and Mobile Medical.
Medical aethetics co. BioForm Medical prices IPO below range, raises up to $92M — BioForm Medical, a wrinkle-treatment maker based in San Mateo, Calif., priced… Continue Reading
Life sciences briefing: Thursday, Nov. 1, 2007
Featured companies: Asteres, HemaQuest Pharmaceuticals, Nanosphere, Novalar Pharmaceuticals, Tranzyme Pharma
(UPDATED: Expanded items for Nanosphere, HemaQuest and Transzyme. Moved Novalar to a separate item here.)
Diagnostic maker Nanosphere prices IPO at low end of range, raises up to $113M — Nanosphere, a Northbrook, Ill., biotech focused on nanotech-derived diagnostics,… Continue Reading
Life sciences briefing: Wednesday, Oct. 31, 2007
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.
U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused… Continue Reading
Life sciences briefing: Tuesday, Oct. 30, 2007
Featured companies: Acceleron Pharma, Bledsoe Brace Systems, Eurobiobiz, Genoptix, Harmony Information Systems, ImmuneWorks, Pasteuria Bioscience, Renal CarePartners, Quantum Genomics, Synergy Software, Vitreo Retinal Technology
UPDATED: Expanded items on Genoptix and Acceleron Pharma.
Diagnostics biotech Genoptix prices IPO above range, raises up to $98M — Genoptix became one of the… Continue Reading
IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings
Bioheart’s IPO-related chest pains continue — The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with patients’ own muscle stem cells…. Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech… Continue Reading
XDx marks a spot: An $86M IPO for gene-expression diagnostics
(UPDATED: See below.)
When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane, Calif., company joined just a handful of similar molecular-diagnostic companies to test the public markets. XDx specializes in a new type of diagnostic test that measures gene activity —… Continue Reading
Life sciences briefing: Wednesday, Oct. 24, 2007
Featured companies: Angstrom Medica, Asuragen, Aryx Therapeutics, HistoRx, MiMedx, Pioneer Surgical, Transfusion & Transplantation Technologies, Tolerx, Vivo Ventures
UPDATED: Expanded Aryx and XDx items.
UPDATE REDUX: Expanded Tolerx item, moved XDx to a separate post.
Aryx sets IPO range, seeks $92M for redesigned drugs — Fremont, Calif.-based Aryx Pharmaceuticals,… Continue Reading
Life sciences briefing: Tuesday, Oct. 23, 2007
Featured companies: Apex Radiology, Arcxis Biotechnologies, EKR Therapeutics, Franklin & Seidelmann, Michelson Diagnostics, SensiGen, Vascular Closure Systems
UPDATED: Expanded items on Arcxis, Vascular Closure and Archemix.
Arcxis pulls in $2M for DNA tools — Arcxis Biotechnologies, a Pleasanton, Calif., biotech tool maker focused on analysis of DNA and proteins… Continue Reading
Life sciences briefing: Monday, Oct. 22, 2007
Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical
UPDATED: Expanded items on SarCode, Celldex/Avant and Ablynx.
UPDATE REDUX: Added items on BioForm Medical, High-Throughput Genomics and Orchid Cellmark/ReliaGene.
San Francisco’s SarCode draws down $7M for inflammation drugs — The… Continue Reading
Life sciences briefing: Thursday, Oct. 18, 2007
Featured companies: American Oriental Bioengineering, Guangxi Boke, Inspired Technologies, Nanosphere, Patton Medical Devices
UPDATED: Expanded items on Nanosphere and Patton Medical Devices.
Molecular-diagnostics firm Nanosphere sets IPO range, now expects $129M — Northbrook, Ill.-based Nanosphere, a maker of nanotech-derived molecular diagnostics, now expects to raise up to $129 million… Continue Reading
I told you so: Eat your Bioheart out
(UPDATED: See below.)
I’m not usually one to gloat — oh, who are we kidding? The news today that Bioheart, an oddball “adult” stem-cell company based in Sunrise, Fla., has slashed its IPO price range — essentially halving the company’s value — and fired its underwriters may… Continue Reading